The Hypoxia drugs in development market research report provides comprehensive information on the therapeutics under development for Hypoxia, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Hypoxia. Buy the report here.

Smarter leaders trust GlobalData


Data Insights Hypoxia - Drugs In Development, 2023

Buy the Report

Data Insights

The gold standard of business intelligence.

Find out more

The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Hypoxia and features dormant and discontinued products.

GlobalData tracks 13 drugs in development for Hypoxia by ten companies/universities/institutes. The top development phase for Hypoxia is preclinical with seven drugs in that stage. The Hypoxia pipeline has 12 drugs in development by companies and one by universities/ institutes. Some of the companies in the Hypoxia pipeline products market are: Bioxytran, Aodh Lifesciences and Stream Biomedical.

The key targets in the Hypoxia pipeline products market include Nitric Oxide Synthase Brain (Constitutive NOS or NC NOS or Neuronal NOS or bNOS or NOS Type I or Peptidyl Cysteine S Nitrosylase NOS1 or NOS1 or EC, Nitric Oxide Synthase Inducible (Hepatocyte NOS or Inducible NO Synthase or Peptidyl Cysteine S Nitrosylase NOS2 or NOS Type II or NOS2 or EC, and Hemoglobin.

The key mechanisms of action in the Hypoxia pipeline product include Nitric Oxide Synthase Inducible (Hepatocyte NOS or Inducible NO Synthase or Peptidyl Cysteine S Nitrosylase NOS2 or NOS Type II or NOS2 or EC Inhibitor with one drug in Phase II. The Hypoxia pipeline products include five routes of administration with the top ROA being Intravenous and five key molecule types in the Hypoxia pipeline products market including Small Molecule, and Polymer.

Hypoxia overview

Hypoxia is a condition in which oxygen is not available in sufficient amounts at the tissue level to maintain adequate homeostasis; this can result from inadequate oxygen delivery to the tissues either due to low blood supply or low oxygen content in the blood (hypoxemia). Hypoxia can vary in intensity from mild to severe and can present in acute or chronic form.

For a complete picture of Hypoxia’s pipeline drug market, buy the report here.

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.